Covid-19 roundup: CanSi­no beats Mod­er­na to pub­li­ca­tion of first-in-hu­man da­ta for a coro­n­avirus vac­cine

Chi­na’s CanSi­no Bi­o­log­ics has re­leased re­sults from the Phase I tri­al of its Covid-19 vac­cine — da­ta that have pro­pelled its en­try in­to Phase II more than a month ago.

In a pa­per pub­lished in the Lancet, the biotech re­port­ed that their ade­n­ovirus-based vac­cine was “tol­er­a­ble and im­muno­genic at 28 days post-vac­ci­na­tion” among the 195 vol­un­teers en­rolled in the tri­al. In ad­di­tion to an­ti­body re­spons­es, T cell re­spons­es were al­so ob­served.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER